The Interim Report of the Investigational New Drug trial on the use of Iplex (mecasermin rinfabate) by middle-to-late stage Amyotrophic Lateral Sclerosis patients has been filed with the FDA, Insmed and Alpha Institutional Review Board. This report will be reprinted on this website once the requisite minimum thirty day waiting period is completed. Thank you for your patience.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.